Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 | P12268 | 1/20 | 0.32 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.32 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | PDE4A | P27815 | 1/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.31 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31322752 | 0.82 | CYP4F2 (0.33) | CYP4F2CYP4A11SLC6A2SLC6A4PDE4A | |
| SCHEMBL31322728 | 0.81 | — | — | |
| SCHEMBL24458092 | 0.75 | SHBG (0.36) | CYP4F2CYP4A11PDE4APDE4BPDE4C | |
| SCHEMBL13082486 | 0.75 | CYP4F2 (0.35) | CYP4F2CYP4A11PDE4APDE4BPDE4C | |
| SCHEMBL25612488 | 0.74 | POLB (0.40) | — | |
| SCHEMBL25616004 | 0.72 | CYP4F2 (0.33) | CYP4F2CYP4A11PDE4APDE4BPDE4C | |
| SCHEMBL28144588 | 0.72 | CYP4F2 (0.33) | CYP4F2CYP4A11PDE4APDE4BPDE4C | |
| SCHEMBL286513 | 0.72 | CYP4F2 (0.33) | CYP4F2CYP4A11PDE4APDE4BPDE4C | |
| SCHEMBL16065518 | 0.72 | CA12 (0.39) | — | |
| SCHEMBL16957698 | 0.68 | PDCD1 (0.50) | SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025038462-A2 | INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF | ACCENT THERAPEUTICS, INC. (US) | 2025-02-20 | — | — | WO | disclosed |